In today’s biopharma economy, declining R&D productivity combined with increased development costs have made investment portfolio managers skittish, says Chip Gillooly, VP, capital, at Quintiles.
“The risks associated with investments are high, and the lack of output is making everyone nervous,” he says. “To manage this new high-risk environment, and continue to deliver valuable and accessible therapies, biopharma companies must find ways to increase output, decrease costs, and eliminate unnecessary layers of bureaucracy that hinder productivity. As new drug applications arising from discovery efforts have dried up, investors…
Experts on this Topic
Chip Gillooly, VP, capital, at Quintiles.
James DeSanti, founder and CEO of PharmaVigilant
Nagaraja Srivatsan, VP and head of life sciences, North America, Cognizant
Kevin Hrusovsky, president and CEO of Caliper Life Sciences
Robin Winter-Sperry, M.D., president and CEO, Scientific Advantage, and Science Oriented Solutions (SOS)
Darshan Kulkarni, Pharm.D, Esq., principal attorney, Kulkarni
Fran DeGrazio, VP, marketing and strategic business development, at West Pharmaceutical Services
Mark Goldberg, M.D., chief operating officer, Parexel International
Michael Parisi, president of Altum, part of CommonHealth
Michael Naimoli, U.S. life sciences industry solutions director, Microsoft
Scott Treiber, executive VP, clinical development solutions, inVentiv Clinical Solutions
Jens Oliver Funk, M.D., senior VP and global head of TA oncology at EMD Serono
Clare Colletti, inVentiv Advance Insights